Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|January 7, 2014
Targeted Therapies in Bladder Cancer
Author(s)Matthew D. Galsky, MD
Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.
Advertisement
Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses targeted therapy treatments for bladder cancer.
Clinical Pearls:
- Targeting tumor angiogenesis and HSP27 could prove to be promising approaches in the treatment of bladder cancer
- While studies that are looking at anti-angiogenic approaches in bladder cancer have shown that the majority of patients do not respond, some patients did respond
- The combination of conventional chemotherapy and anti-angiogenic drugs is difficult to give because they have some overlapping side effects
- Targeting VEGF with an antibody might be more promising in terms of the ability to deliver both drugs effectively without overlapping toxicities
- A study that is exploring gemcitabine and cisplatin with or without bevacizumab should establish a role for this class of drugs in the treatment of bladder cancer
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5